BioPharma Resources

Drug Trial Radar · NCT07484074

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Two Different Formulations of Intravitreal OLN324 in Adult Participants With Either Neovascular (Wet) Age-related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

164

Actual

Start

Feb 12, 2025

Primary completion

Oct 10, 2025

Study completion Dec 9, 2025

Sponsor

Lead sponsor
Ollin Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

Conditions

  • Diabetic Macular Edema (DME)
  • Neovascular (Wet) Age-Related Macular Degeneration

Interventions

  • FaricimabDrug

    Intravitreal Injection

  • OLN324Drug

    Intravitreal Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse EventsTime frame: Week 12 and Week 20

Locations

30 sites in 2 countries. Site status is shown where the registry gives one.

  • Phoenix, AZ

    Phoenix, Arizona

  • Glendale, CA

    Glendale, California

  • Pasadena, CA

    Pasadena, California

  • Sacramento, CA

    Sacramento, California

  • Walnut Creek, CA

    Walnut Creek, California

  • Waterford, CT

    Waterford, Connecticut

  • Fort Myers, FL

    Fort Myers, Florida

  • Saint Petersburg, FL

    St. Petersburg, Florida

  • Winter Haven, FL

    Winter Haven, Florida

  • Oak Forest, IL

    Oak Forest, Illinois

  • Hagerstown, MD

    Hagerstown, Maryland

  • Grand Rapids, MI

    Grand Rapids, Michigan

  • Reno, NV

    Reno, Nevada

  • Wake Forest, NC

    Wake Forest, North Carolina

  • Tulsa, OK

    Tulsa, Oklahoma

  • Springfield, OR

    Springfield, Oregon

  • Germantown, TN

    Germantown, Tennessee

  • Abilene, TX

    Abilene, Texas

  • Arlington, TX

    Arlington, Texas

  • Austin, TX

    Austin, Texas

  • Bellaire, TX

    Bellaire, Texas

  • Dallas, TX

    Dallas, Texas

  • Katy, TX

    Katy, Texas

  • Plano, TX

    Plano, Texas

  • Round Rock, TX

    Round Rock, Texas

  • San Antonio, TX

    San Antonio, Texas

  • San Marcos, TX

    San Marcos, Texas

  • Schertz, TX

    Schertz, Texas

  • The Woodlands, TX

    The Woodlands, Texas

  • Arecibo, Puerto Rico

    Arecibo, Puerto Rico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.